Tokyo, Japan & Global Markets – Daiichi Sankyo has marked a significant milestone in its ongoing commitment to advancing oncology therapeutics with the announcement of the first patient dosed in a Phase I clinical trial for its investigational antibody-drug conjugate (ADC), DS1025. This trial will explore the potential of DS1025 in adult patients grappling with advanced or metastatic solid tumors who have exhausted previous standard treatment options and experienced disease progression. The innovative ADC is engineered to specifically target cluster of differentiation 25 (CD25), a key protein found on regulatory T cells (Treg cells) that play a crucial role in dampening the body’s natural anti-cancer immune response.
The initiation of this trial underscores Daiichi Sankyo’s strategic focus on leveraging cutting-edge technologies like ADCs to overcome treatment resistance and improve outcomes for patients with challenging cancers. DS1025 represents the latest advancement stemming from the company’s proprietary DXd ADC technology platform, a platform that has already demonstrated remarkable success in delivering highly potent cytotoxic agents directly to tumor cells while minimizing systemic toxicity.
Unveiling DS1025: A Targeted Approach to Immune Modulation in Cancer
DS1025 is a novel ADC designed with a precise therapeutic strategy in mind: to target CD25. This protein is predominantly expressed on the surface of regulatory T cells (Tregs), a subset of immune cells that are essential for maintaining immune homeostasis. While Tregs play a vital role in preventing autoimmune diseases and excessive inflammation, their presence in the tumor microenvironment can be detrimental to anti-cancer immunity. By suppressing the activity of effector T cells that are meant to attack cancer cells, Tregs can create an immunosuppressive shield around tumors, hindering the effectiveness of various cancer treatments, including immunotherapies.
The mechanism of action for DS1025 is anticipated to involve the selective binding of its antibody component to CD25 on Treg cells. Upon internalization, the potent cytotoxic payload conjugated to the antibody is released, leading to the targeted elimination of these immunosuppressive cells. This depletion of Tregs is hypothesized to reawaken the anti-tumor immune response, making the tumor more susceptible to eradication by the patient’s own immune system and potentially enhancing the efficacy of other cancer therapies.
The Phase I Trial: A Multi-Site, Global Endeavor
The open-label, dose escalation, multi-center Phase I clinical trial is designed to meticulously evaluate the safety, pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes the drug), tolerability, and preliminary efficacy of DS1025. The trial’s design prioritizes patient safety and aims to identify the optimal dose and schedule for further clinical development.
Key Objectives of the Trial:
-
Primary Objectives:
- Tolerability and Safety Assessment: This is the cornerstone of any Phase I trial. Researchers will closely monitor for any adverse events (AEs) that may occur, their severity, and their relationship to the investigational drug. A critical aspect of this assessment is the identification of dose-limiting toxicities (DLTs), which are unacceptable toxicities that limit the maximum tolerated dose (MTD). Understanding DLTs is crucial for establishing a safe dose range for future studies.
- Pharmacokinetics (PK): Evaluating the PK profile of DS1025 will provide vital information on how the drug behaves in the body. This includes determining the absorption rate, peak plasma concentration, half-life, and routes of elimination. This data is essential for understanding drug exposure and informing dosing strategies.
-
Secondary Objectives:
- Pharmacokinetics (PK) (Further Evaluation): Building upon the initial PK assessment, secondary objectives may delve deeper into specific PK parameters or explore PK in different patient populations.
- Immunogenicity: The trial will also assess the potential for the human body to develop an immune response against DS1025 itself. The development of anti-drug antibodies (ADAs) can sometimes affect the drug’s efficacy or safety profile.
-
Exploratory Endpoints:
- Overall Response Rate (ORR): This is a measure of how many patients achieve a partial or complete response to the treatment, as determined by objective tumor shrinkage.
- Duration of Response (DoR): For patients who respond, this endpoint measures how long that response is maintained.
- Time to Response (TTR): This measures the time it takes for a patient to achieve an objective response after starting treatment.
The trial is set to recruit up to 45 patients across multiple clinical sites strategically located in both Asia and Europe. This global reach ensures a diverse patient population and facilitates efficient patient recruitment, accelerating the trial’s progress.
A Foundation of Innovation: Daiichi Sankyo’s DXd ADC Technology
The development of DS1025 is deeply rooted in Daiichi Sankyo’s pioneering DXd ADC technology. This proprietary platform has been instrumental in the creation of several successful ADCs, including Enhertu (trastuzumab deruxtecan), which has revolutionized the treatment of HER2-positive breast, gastric, and lung cancers, and is being explored in other HER2-low and HER2-mutated cancers.
The DXd ADC technology involves a unique payload, a cleavable linker, and a highly specific antibody. The linker is designed to be stable in the bloodstream but readily cleaved within tumor cells, ensuring the targeted release of the potent cytotoxic payload. The "DXd" payload itself is a topoisomerase I inhibitor, a class of drugs known for their potent anti-cancer activity. The antibody component is engineered to bind to specific tumor-associated antigens, ensuring that the cytotoxic payload is delivered primarily to cancer cells, thereby minimizing damage to healthy tissues and reducing off-target side effects.
Voices from the Forefront: Leadership Perspectives
Dr. John Tsai, Global Head of Research and Development (R&D) at Daiichi Sankyo, expressed enthusiasm regarding the commencement of the DS1025 trial. He highlighted the ongoing need for innovation in cancer treatment, particularly in harnessing the power of the immune system.
"While immunotherapies have transformed cancer treatment, continued innovation in leveraging pathways that can activate the immune system is needed," Dr. Tsai stated. "The initiation of this trial evaluating DS1025 reflects continued progress in advancing our pipeline through the development of novel antibody drug conjugates in order to deliver medicines that improve outcomes for patients with cancer."
Dr. Tsai’s remarks underscore the strategic importance of DS1025 within Daiichi Sankyo’s broader oncology strategy. The company recognizes that while current immunotherapies have made significant strides, there remains a critical unmet need for therapies that can overcome immune suppression within the tumor microenvironment. By targeting CD25, DS1025 aims to address this challenge directly, potentially unlocking new avenues for patient benefit.
A Comprehensive ADC Portfolio
DS1025 is a testament to Daiichi Sankyo’s expansive commitment to antibody-drug conjugate research and development. The company boasts a robust pipeline of ADCs, with DS1025 being one of nine compounds currently in various stages of clinical development. This extensive portfolio reflects a deep understanding of ADC technology and a commitment to exploring its application across a wide range of cancers and target antigens.
Several of these promising ADCs are being developed and commercialized in collaboration with leading pharmaceutical partners, including AstraZeneca and Merck & Co (MSD). These strategic partnerships leverage the strengths of each company, combining Daiichi Sankyo’s expertise in ADC design and manufacturing with the global reach and clinical development capabilities of its collaborators. Such collaborations are crucial for accelerating the translation of scientific discoveries into life-saving medicines for patients worldwide.
Contextualizing the Advancement: Recent Milestones
The initiation of the DS1025 trial follows a series of significant advancements in Daiichi Sankyo’s oncology pipeline. In December 2025, the company announced the dosing of the first patient in the randomization phase of the DESTINY-Ovarian01 Phase III trial. This pivotal trial is evaluating Enhertu (trastuzumab deruxtecan) in combination with bevacizumab, compared to bevacizumab alone, as a first-line maintenance therapy for ovarian cancer. The success of Enhertu in various indications has set a high benchmark, and the ongoing research in ovarian cancer further highlights Daiichi Sankyo’s dedication to addressing critical unmet needs in gynecological malignancies.
These ongoing clinical trials and the initiation of new ones like the DS1025 study demonstrate Daiichi Sankyo’s unwavering commitment to pushing the boundaries of cancer therapy. The company’s strategic investments in innovative technologies like ADCs, coupled with its collaborative approach and strong R&D leadership, position it as a key player in the global fight against cancer.
Implications for the Future of Cancer Therapy
The Phase I trial of DS1025 holds significant implications for the future of cancer treatment, particularly for patients with advanced solid tumors who have limited therapeutic options.
-
Overcoming Immune Suppression: If DS1025 proves to be safe and effective in depleting immunosuppressive Tregs, it could represent a paradigm shift in how we approach cancer immunotherapy. By restoring the immune system’s ability to recognize and attack cancer cells, DS1025 could potentially enhance the efficacy of existing immunotherapies and even make previously unresponsive tumors susceptible to treatment.
-
Broader Applicability: The targeting of CD25, a protein found on Tregs that are often implicated in immune evasion across various cancer types, suggests that DS1025 could have broad applicability. Successful development could lead to its investigation in a wide range of solid tumors, offering hope to a diverse patient population.
-
Advancing ADC Technology: The continued success and development of novel ADCs like DS1025 reinforce the power and versatility of this therapeutic modality. As ADC technology matures, we can expect to see more sophisticated designs, novel payloads, and targeted delivery systems that further refine their precision and efficacy.
-
Personalized Medicine: Future research may explore combinations of DS1025 with other targeted therapies or immunotherapies, potentially leading to more personalized and effective treatment regimens tailored to the specific characteristics of a patient’s tumor and immune profile.
The journey from Phase I trials to regulatory approval is long and complex, but the initiation of this study for DS1025 marks a crucial step forward. Daiichi Sankyo’s commitment to innovation and its robust pipeline of ADCs offer a beacon of hope for patients battling advanced cancers, signaling a future where more targeted and effective treatments are within reach. The scientific community will be closely watching the progress of this trial, eager to see how DS1025 will contribute to the evolving landscape of oncology.
About the Author
